Literature DB >> 32591471

CSF biomarkers in Olmsted County: Evidence of 2 subclasses and associations with demographics.

Argonde C Van Harten1, Heather J Wiste2, Stephen D Weigand2, Michelle M Mielke2, Walter K Kremers2, Udo Eichenlaub2, Richard Batrla-Utermann2, Roy B Dyer2, Alicia Algeciras-Schimnich2, David S Knopman2, Clifford R Jack2, Ronald C Petersen2.   

Abstract

OBJECTIVE: We studied interrelationships between CSF biomarkers and associations with APOE ε4 genotype, demographic variables, vascular variables, and clinical diagnosis in Olmsted County, Minnesota.
METHODS: We included 774 Mayo Clinic Study of Aging participants (693 cognitively unimpaired [CU]; 71 with mild cognitive impairment [MCI]). CSF β-amyloid 42 (Aβ42), total tau (t-tau), and hyperphosphorylated tau (p-tau) were analyzed using Aβ42 CSF, t-tau CSF, and p-tau (181P) CSF electrochemiluminescence immunoassays. Bivariate mixture models were used to evaluate latent classes. We used linear regression models to evaluate independent associations of APOE ε4, demographic factors, cardiovascular risk, and diagnosis with CSF biomarker levels. Results were weighted back to the Olmsted County population.
RESULTS: Interrelationships between CSF Aβ42 and p-tau/t-tau were consistent with 2 latent classes in the general population. In subgroup 1 (n = 547 [71%]), we found a strong positive correlation between Aβ42 and p-tau (ρ = 0.81), while the correlation was much smaller in group 2 (ρ = 0.26, n = 227 [29%]). Group 2 was associated with older age, APOE ε4 genotype, a diagnosis of MCI, and elevated amyloid PET. Overall, APOE ε4 genotype and MCI were associated with Aβ42, while age was associated with p-tau/t-tau. There were no associations with sex, education, or vascular risk.
CONCLUSION: We hypothesize the population without dementia can be subdivided into participants with and without biological Alzheimer disease (AD) based on the combination of CSF Aβ42 and p-tau/t-tau (represented also by the p-tau/t-tau/Aβ42 ratio). In those without biological AD, common factors such as CSF dynamics may cause a positive correlation between CSF Aβ42 and p-tau/t-tau, while AD leads to dissociation of these proteins.
© 2020 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32591471      PMCID: PMC7455353          DOI: 10.1212/WNL.0000000000009874

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  45 in total

1.  The influence of ageing in the cerebrospinal fluid concentrations of proteins that are derived from the choroid plexus, brain, and plasma.

Authors:  Carl P C Chen; Ruo Li Chen; Jane E Preston
Journal:  Exp Gerontol       Date:  2012-04       Impact factor: 4.032

2.  Mayo's older Americans normative studies: category fluency norms.

Authors:  J A Lucas; R J Ivnik; G E Smith; D L Bohac; E G Tangalos; N R Graff-Radford; R C Petersen
Journal:  J Clin Exp Neuropsychol       Date:  1998-04       Impact factor: 2.475

3.  Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca
Journal:  Int J Epidemiol       Date:  2012-11-18       Impact factor: 7.196

4.  Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia.

Authors:  Clifford R Jack; Heather J Wiste; Terry M Therneau; Stephen D Weigand; David S Knopman; Michelle M Mielke; Val J Lowe; Prashanthi Vemuri; Mary M Machulda; Christopher G Schwarz; Jeffrey L Gunter; Matthew L Senjem; Jonathan Graff-Radford; David T Jones; Rosebud O Roberts; Walter A Rocca; Ronald C Petersen
Journal:  JAMA       Date:  2019-06-18       Impact factor: 56.272

5.  Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults.

Authors:  Donata Paternicò; Samantha Galluzzi; Valeria Drago; Luisella Bocchio-Chiavetto; Roberta Zanardini; Laura Pedrini; Manuela Baronio; Giovanni Amicucci; Giovanni B Frisoni
Journal:  Alzheimers Dement       Date:  2012-06-06       Impact factor: 21.566

6.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; Terry M Therneau; Val J Lowe; David S Knopman; Jeffrey L Gunter; Matthew L Senjem; David T Jones; Kejal Kantarci; Mary M Machulda; Michelle M Mielke; Rosebud O Roberts; Prashanthi Vemuri; Denise A Reyes; Ronald C Petersen
Journal:  Alzheimers Dement       Date:  2016-09-30       Impact factor: 21.566

7.  Late-Life Vascular Risk Factors and Alzheimer Disease Neuropathology in Individuals with Normal Cognition.

Authors:  Lilah M Besser; Michael L Alosco; Liliana Ramirez Gomez; Xiao-Hua Zhou; Ann C McKee; Robert A Stern; John Gunstad; Julie A Schneider; Helena Chui; Walter A Kukull
Journal:  J Neuropathol Exp Neurol       Date:  2016-08-11       Impact factor: 3.685

8.  The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics.

Authors:  Rosebud O Roberts; Yonas E Geda; David S Knopman; Ruth H Cha; V Shane Pankratz; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Ronald C Petersen; Walter A Rocca
Journal:  Neuroepidemiology       Date:  2008-02-07       Impact factor: 3.282

9.  Temporal course of cerebrospinal fluid dynamics and amyloid accumulation in the aging rat brain from three to thirty months.

Authors:  Catherine Chiu; Miles C Miller; Ilias N Caralopoulos; Michael S Worden; Thomas Brinker; Zachary N Gordon; Conrad E Johanson; Gerald D Silverberg
Journal:  Fluids Barriers CNS       Date:  2012-01-23

Review 10.  Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.

Authors:  Oskar Hansson; Sylvain Lehmann; Markus Otto; Henrik Zetterberg; Piotr Lewczuk
Journal:  Alzheimers Res Ther       Date:  2019-04-22       Impact factor: 6.982

View more
  10 in total

1.  Cerebrospinal fluid dynamics and discordant amyloid biomarkers.

Authors:  Jonathan Graff-Radford; David T Jones; Heather J Wiste; Petrice M Cogswell; Stephen D Weigand; Val Lowe; Benjamin D Elder; Prashanthi Vemuri; Argonde Van Harten; Michelle M Mielke; David S Knopman; Neill R Graff-Radford; Ronald C Petersen; Clifford R Jack; Jeffrey L Gunter
Journal:  Neurobiol Aging       Date:  2021-11-01       Impact factor: 4.673

2.  CSF phosphorylated tau as an indicator of subsequent tau accumulation.

Authors:  Petrice M Cogswell; Heather J Wiste; Michelle M Mielke; Christopher G Schwarz; Stephen D Weigand; Val J Lowe; Terry M Therneau; David S Knopman; Jonathan Graff-Radford; Prashanthi Vemuri; Matthew L Senjem; Jeffrey L Gunter; Alicia Algeciras-Schimnich; Ronald C Petersen; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2022-05-26       Impact factor: 5.133

3.  Data-Driven vs Consensus Diagnosis of MCI: Enhanced Sensitivity for Detection of Clinical, Biomarker, and Neuropathologic Outcomes.

Authors:  Emily C Edmonds; Denis S Smirnov; Kelsey R Thomas; Lisa V Graves; Katherine J Bangen; Lisa Delano-Wood; Douglas R Galasko; David P Salmon; Mark W Bondi
Journal:  Neurology       Date:  2021-08-10       Impact factor: 11.800

4.  Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years: An ADNI Study.

Authors:  Keith A Josephs; Stephen D Weigand; Jennifer L Whitwell
Journal:  Neurology       Date:  2022-03-21       Impact factor: 11.800

5.  Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease.

Authors:  Vijay K Ramanan; Michael G Heckman; Timothy G Lesnick; Scott A Przybelski; Elliot J Cahn; Matthew L Kosel; Melissa E Murray; Michelle M Mielke; Hugo Botha; Jonathan Graff-Radford; David T Jones; Val J Lowe; Mary M Machulda; Clifford R Jack; David S Knopman; Ronald C Petersen; Owen A Ross; Prashanthi Vemuri
Journal:  Acta Neuropathol       Date:  2022-04-12       Impact factor: 15.887

Review 6.  Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes.

Authors:  Teresa Gómez-Isla; Matthew P Frosch
Journal:  Nat Rev Neurol       Date:  2022-03-24       Impact factor: 44.711

7.  β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer's disease and predicts cerebral amyloidosis.

Authors:  Tao-Ran Li; Yun-Xia Yao; Xue-Yan Jiang; Qiu-Yue Dong; Xian-Feng Yu; Ting Wang; Yan-Ning Cai; Ying Han
Journal:  Alzheimers Res Ther       Date:  2022-05-12       Impact factor: 8.823

8.  Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays.

Authors:  Argonde C van Harten; Heather J Wiste; Stephen D Weigand; Michelle M Mielke; Walter K Kremers; Udo Eichenlaub; Roy B Dyer; Alicia Algeciras-Schimnich; David S Knopman; Clifford R Jack; Ronald C Petersen
Journal:  Alzheimers Dement       Date:  2021-07-26       Impact factor: 16.655

9.  Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile.

Authors:  Marta Milà-Alomà; Mahnaz Shekari; Gemma Salvadó; Juan Domingo Gispert; Eider M Arenaza-Urquijo; Grégory Operto; Carles Falcon; Natalia Vilor-Tejedor; Oriol Grau-Rivera; Aleix Sala-Vila; Gonzalo Sánchez-Benavides; José Maria González-de-Echávarri; Carolina Minguillon; Karine Fauria; Aida Niñerola-Baizán; Andrés Perissinotti; Maryline Simon; Gwendlyn Kollmorgen; Henrik Zetterberg; Kaj Blennow; Marc Suárez-Calvet; José Luis Molinuevo
Journal:  Alzheimers Res Ther       Date:  2021-07-27       Impact factor: 6.982

10.  Arterial stiffening acts synergistically with APOE genotype and AD biomarker status to influence memory in older adults without dementia.

Authors:  Katherine J Bangen; Denis S Smirnov; Lisa Delano-Wood; Christina E Wierenga; Mark W Bondi; David P Salmon; Douglas Galasko
Journal:  Alzheimers Res Ther       Date:  2021-07-01       Impact factor: 6.982

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.